NCT02926170View on ClinicalTrials.gov

Rivaroxaban for Patients With Antiphospholipid Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

March 13, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Antiphospholipid Syndrome
Interventions
DRUG

Rivaroxaban

Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.

DRUG

acenocumarol

Doses will be adjusted according to INR

Trial Locations (1)

08035

Vall d'Hebron University Hospital, Barcelona

All Listed Sponsors
lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT02926170 - Rivaroxaban for Patients With Antiphospholipid Syndrome | Biotech Hunter | Biotech Hunter